Newsroom | 4955 results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the “Issuers”), have priced the offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 (“Notes”). The size of the offering was incre...

ANN ARBOR, Mich.--(BUSINESS WIRE)--Sling Therapeutics Appoints Ken Lock as Chief Commercial Officer...

MELBOURNE, Australia & FORT WORTH, Texas--(BUSINESS WIRE)--PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced two major milestones in its next phase of growth: the appointment of seasoned biopharmaceutical executive, Jerry St. Peter as CEO and board director, and the successful close of a $25M Series C funding round led by an Australian Sovereign Wealth Fund with continued st...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. “We are excited to welcome Mike to the Harrow Family. His wealth of exper...

ATHERTON, Calif.--(BUSINESS WIRE)--Amaros Inc. (www.amaros.ai), a leader in ophthalmic intelligence and the developer of AI-powered EvidenceEngine platform, today announced the successful close of its Series A financing. Backed by a select group of new and existing mission-aligned investors, the round validates Amaros' mission to transform fragmented clinical data into real-time, actionable intelligence for eye care. “This funding confirms our core belief that ophthalmology’s most underutilized...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. Per FDA agreement, the only...

DURHAM, N.C.--(BUSINESS WIRE)--Sightview, the only electronic health record and practice management partner focused solely on eyecare, has named Tycene Fritcher as CEO....

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, con...

ソルトレイクシティ--(BUSINESS WIRE)--（ビジネスワイヤ） -- HOYAビジョンケア（https://www.hoyavision.com/）はDIMA技術の影響を浮き彫りにする3つの臨床試験から得られた新しいエビデンスを発表 しました。本結果は、ユタ州ソルトレイクシティで開催された2025年視覚と眼科学研究協会（ARVO）年次総会において、同社の2025年科学プログラム「MiYOSMART*による近視管理の新たなフロンティアの探求」の一環として発表されました。 近視管理用眼鏡レンズに関する世界最長の臨床試験から得られた最新の知見により、DIMSレンズを継続して装用した場合、近視進行（-1.00D ± 0.41D、p＝0.017）および眼軸長の延長（0.42 ± 0.18mm、p＝0.019）が8年間（n＝11）の追跡期間を通じて一貫して有意に抑制されたことが示されました。1 この結果は、MiYOSMART*眼鏡レンズの継続的な長期の装着が、近視管理の転帰を改善すると示唆しています。 HOYAビジョンケアのメディカル・サイエンティフィック・アフェアーズのグローバルヘ...

SALT LAKE CITY--(BUSINESS WIRE)--HOYA Vision Care (https://www.hoyavision.com/) oggi ha annunciato una nuova evidenza clinica proveniente da tre studi clinici chiave che evidenziano l'impatto della tecnologia D.I.M.S. (Defocus Incorporated Multiple Segments). I risultati sono stati presentati nell'ambito del programma scientifico 2025 dell'azienda, Exploring New Frontiers in Myopia Management with MiYOSMART* (L'esplorazione di nuove frontiere nella gestione della miopia con MiYOSMART), al Congr...